Work

Abstract CT188: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2024-ct188

Authors: Udai Banerji, Natalie Cook, Alan Anthoney, Ruth Plummer, William D. Tap, Jeffry T. Evans, Lee D. Cranmer, Christopher Plummer, Paul Loadman, Gezim Lahu, Huw S. Jones, Nelson Kinnersley, Fiona McLaughlin, Chris Twelves

Institutions: Institute of Cancer Research, The Christie NHS Foundation Trust, University of Leeds, Newcastle University, Memorial Sloan Kettering Cancer Center, University of Glasgow, University of Washington, Fred Hutch Cancer Center, University of Bradford

Language: English

Topic: Peptidase Inhibition and Analysis

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4393983002

Cites:

Cited by: 2

Related to: 10